Delivery Order SPE2DB24D8003-SPE2DB25FJUHV
Award Date
5/1/25
Potential Completion Date
5/2/25
Potential Value
$2.4K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $7,091.73 to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. This contract, with a performance period ending on March 4, 2024, is for the delivery of Dupixent 300 mg/2 ml syringes. This award is part of a larger Indefinite Delivery Contract (IDC), identified as SPE2DB24D8001, which allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $4,194.83 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml pens. This contract falls under Dakota Drug's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which procures medical equipment, accessories, consumables, and simulation equipment. The contract has an ultimate...
This is a federal contract award by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,722.06 Firm Fixed Price Delivery Order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML pharmaceutical products. The contract has an ultimate completion date of February 5, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to provide a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $7,274.15 firm fixed-price delivery order is for the pharmaceutical product DUPIXENT 300 MG/2 ML SYRINGE 2ML, with a period of performance through February 1, 2024. Dakota Drug, Inc. holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, as part of the ECAT Generation V Program, which allows the...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,867.25 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product. The award is not associated with a set-aside program. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the DLA Troop Support Medical's ECAT...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $4,644.03, is for the delivery of Dupixent 300 mg/2 ml pens, a pharmaceutical product. The contract has a firm fixed price pricing type and a performance period ending on June 5, 2024. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical division to Dakota Drug, Inc., a self-certified small disadvantaged business. The $11,049.12 firm fixed-price delivery order contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML medical products. This award is part of Dakota Drug's existing $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA, SPE2DB24D8001, under the ECAT Generation V Program. The contract has a period of...
This federal contract award was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml pens. The contract, identified as SPE2DB24D8001|SPE2DB25FKZCU, has a ceiling value of $6,688.11 and a period of performance through January 30, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00, which is part of the DLA Troop Support Medical's ECAT...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $2,673.87 to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of 4567655331 DUPIXENT 300 MG/2 ML PEN 2ML. This contract has an ultimate completion date of March 24, 2025 and was awarded on March 21, 2025. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide range of pharmaceutical products, medical supplies, and...
This federal contract award, identified as SPE2DB24D8001 and SPE2DB25FKZDB, was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $5,784.90 firm fixed-price delivery order is for the provision of DUPIXENT 300 MG/2 ML PEN 2ML, a pharmaceutical product. The award is part of Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, which allows the company to supply a comprehensive range...